Dr Phoebe Li is the Principal Investigator on the EPSRC/Cambridge Re-distributed manufacturing in 3D bioprinting (RDM in 3DP) project.

She is also the Co-Investigator for the BioMod and BioGov projects (led by Oxford, York and Sussex Universities), examining the regulation and governance models of cutting-edge biotechnologies including 3D bioprinting, gene editing and iPSC. The interdisciplinary research group on digital health and biolaw has been actively engaged in national and international governmental policymaking which includes the following activities:

• Working with the UK Parliament Office of Science and Technology (POST) on the Research Briefing POSTNote ‘3D bioprinting in medicine’ March 2020.

• Taking part in European Parliamentary Research Service, European Parliament, Scientific Foresight Unit (STOA) ‘3D bio-printing for medical and enhancement purposes: legal and ethical aspects’ (2018) PE 614.571

• Advising the 3D Bioprinting Pioneering project for the Taiwan Food and Drug Administration (TFDA). 

• Sitting on the Digital Hospital initiative which incorporates digital biofabrication in remote healthcare between the UK and Peru partnership (funded by the British Council, 2019).

• Contributing to policy briefs on biomodifying technologies: Making ‘good targets’ for translational research: policy Briefing July 2020. Biomodifying Technologies: Accelerating innovation: Policy Briefing 2020 (published on the Regmednet page: (3 Sep 2020); Policy briefing: Trends in customization and personalization of advanced therapies (1 Feb 2021)